@article {Lapointe-Shaw2020.05.19.20107391, author = {Lauren Lapointe-Shaw and Benjamin Rader and Christina M. Astley and Jared B. Hawkins and Deepit Bhatia and William J. Schatten and Todd C. Lee and Jessica J. Liu and Noah M. Ivers and Nathan M. Stall and Effie Gournis and Ashleigh R. Tuite and David N. Fisman and Isaac I. Bogoch and John S. Brownstein}, title = {Syndromic Surveillance for COVID-19 in Canada}, elocation-id = {2020.05.19.20107391}, year = {2020}, doi = {10.1101/2020.05.19.20107391}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background Syndromic surveillance through web or phone-based polling has been used to track the course of infectious diseases worldwide. Our study objective was to describe the characteristics, symptoms, and self-reported testing rates of respondents in three different COVID-19 symptom surveys in Canada.Methods Data sources consisted of two distinct Canada-wide web-based surveys, and phone polling in Ontario. All three sources contained self-reported information on COVID-19 symptoms and testing. In addition to describing respondent characteristics, we examined symptom frequency and the testing rate among the symptomatic, as well as rates of symptoms and testing across respondent groups.Results We found that 1.6\% of respondents experienced a symptom on the day of their survey, 15\% of Ontario households had a symptom in the previous week, and 44\% of Canada-wide respondents had a symptom in the previous month over March-April 2020. Across the three surveys, SARS-CoV-2-testing was reported in 2-9\% of symptomatic responses. Women, younger and middle-aged adults (versus older adults) and Indigenous/First nations/Inuit/M{\'e}tis were more likely to report at least one symptom, and visible minorities were more likely to report the combination of fever with cough or shortness of breath.Interpretation The low rate of testing among those reporting symptoms suggests significant opportunity to expand testing among community-dwelling residents of Canada. Syndromic surveillance data can supplement public health reports and provide much-needed context to gauge the adequacy of current SARS-CoV-2 testing rates.Competing Interest StatementWJ Schatten is a paid employee for Forum Research. II Bogoch has consulted to BlueDot, a social benefit corporation that tracks the spread of emerging infectious diseases. The remaining authors have no competing interests.Funding StatementThis work did not receive specific funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript are the property of Forum Research, Angus Reid and COVID Near You.}, URL = {https://www.medrxiv.org/content/early/2020/05/26/2020.05.19.20107391}, eprint = {https://www.medrxiv.org/content/early/2020/05/26/2020.05.19.20107391.full.pdf}, journal = {medRxiv} }